COL15A1 and sarcopenia: This disruption may impair the normal function of muscle cells, leading to pathological changes in muscles, including muscle cell atrophy, weakened muscle strength, and potentially resulting in the development of muscle diseases such as sarcopenia.S3, S4 Currently, COL15A1 formulations have been approved for clinical use, such as collagenase Clostridium histolyticum, which has received FDA approval for the removal of necrotic tissue in burns and skin ulcers, as well as the treatment of Dupuytren's contracture and Peyronie's disease37 38.